​

Solid Biosciences (SLDB) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

SLDB Stock Forecast

Solid Biosciences (SLDB) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $17.50, with a high of $20.00 and a low of $12.00. This represents a 586.27% increase from the last price of $2.55.

- $4 $8 $12 $16 $20 High: $20 Avg: $17.5 Low: $12 Last Closed Price: $2.55

SLDB Stock Rating

Solid Biosciences stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (66.67%), 5 Hold (27.78%), 1 Sell (5.56%), and 0 Strong Sell (0.00%).

Buy
Total 18 1 5 12 0 Strong Sell Sell Hold Buy Strong Buy

SLDB Price Target Upside V Benchmarks

TypeNameUpside
StockSolid Biosciences586.27%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$16.67
Last Closing Price$2.55$2.55$2.55
Upside/Downside--553.73%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2557---12
Mar, 2557---12
Feb, 2557---12
Jan, 2557---12
Dec, 2456---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 24, 2024Joseph SchwartzLeerink Partners$12.00$6.6281.27%370.59%
May 31, 2024Biren AminPiper Sandler$20.00$7.64161.78%684.31%
May 16, 2024Gena WangBarclays$18.00$9.6985.76%605.88%
Mar 13, 2024Christopher RaymondRaymond James$20.00$12.2363.53%684.31%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 14, 2024H.C. WainwrightBuyBuyhold
Jun 24, 2024Leerink PartnersOutperformupgrade
Jun 21, 2024Piper SandlerOverweightOverweighthold
May 16, 2024BarclaysOverweightOverweighthold
Mar 28, 2024William BlairOutperforminitialise
Mar 13, 2024Piper SandlerNeutralOverweightupgrade
Apr 28, 2022Piper SandlerNeutralNeutralhold
Apr 28, 2022SVB LeerinkOutperformOutperformhold
Apr 28, 2022Chardan CapitalBuyBuyhold

Financial Forecast

EPS Forecast

$-11 $-9 $-7 $-5 $-3 $-1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-10.13$-7.70$-4.83$-3.06----
Avg Forecast$-10.77$-6.83$-4.76$-2.89$-2.90$-2.79$-3.03$-2.00
High Forecast$-10.77$-6.83$-3.91$-2.71$-2.09$-1.83$-2.26$-2.00
Low Forecast$-10.77$-6.83$-5.16$-3.03$-3.60$-4.46$-5.18$-2.00
Surprise %-5.94%12.74%1.47%5.88%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$13.62M$8.09M------
Avg Forecast$12.10M$8.10M$1.10M$1.21M$1.49M$2.34M$22.70M$116.10M
High Forecast$12.10M$8.10M$1.10M$1.21M$1.49M$2.34M$22.70M$116.10M
Low Forecast$12.10M$8.10M$1.10M$1.21M$1.49M$2.34M$22.70M$116.10M
Surprise %12.57%-0.05%------

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-72.12M$-65.51M$-96.02M$-124.70M----
Avg Forecast$-214.15M$-135.78M$-96.02M$-57.04M$-56.62M$-62.58M$-73.92M$-39.67M
High Forecast$-214.15M$-135.78M$-77.65M$-53.90M$-41.64M$-36.45M$-44.90M$-39.67M
Low Forecast$-214.15M$-135.78M$-102.61M$-60.18M$-71.59M$-88.72M$-102.95M$-39.67M
Surprise %-66.32%-51.75%-118.61%----

SLDB Forecast FAQ

Is Solid Biosciences stock a buy?

Solid Biosciences stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 5 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Solid Biosciences is a favorable investment for most analysts.

What is Solid Biosciences's price target?

Solid Biosciences's price target, set by 18 Wall Street analysts, averages $17.5 over the next 12 months. The price target range spans from $12 at the low end to $20 at the high end, suggesting a potential 586.27% change from the previous closing price of $2.55.

How does Solid Biosciences stock forecast compare to its benchmarks?

Solid Biosciences's stock forecast shows a 586.27% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Solid Biosciences over the past three months?

  • April 2025: 41.67% Strong Buy, 58.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 41.67% Strong Buy, 58.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 41.67% Strong Buy, 58.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Solid Biosciences’s EPS forecast?

Solid Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.9, marking a -5.23% decrease from the reported $-3.06 in 2024. Estimates for the following years are $-2.79 in 2026, $-3.03 in 2027, and $-2 in 2028.

What is Solid Biosciences’s revenue forecast?

Solid Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $1.49M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $2.34M, followed by $22.7M for 2027, and $116.1M for 2028.

What is Solid Biosciences’s net income forecast?

Solid Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-56.618M, representing a -54.60% decrease from the reported $-125M in 2024. Projections indicate $-62.585M in 2026, $-73.922M in 2027, and $-39.669M in 2028.